Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Apimeds Pharmaceuticals US, Inc
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 1.54M shares outstanding
USApimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
Leadership
Erik C. Emerson
President
Christopher Kim
Chief Medical Officer
Erick J. Frim
Chief Financial Officer
Amardeep Singh
Chief Technology Officer
Employees
7
Country
US
Sector
Healthcare
Website
apimedsus.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Koo Jakap | Director | Grant/Award | 10.0K | -- | Nov 11, 2025 |
 Kogan Elona | Director | Grant/Award | 10.0K | -- | Nov 11, 2025 |
 Weintraub Bennett | Director | Grant/Award | 10.0K | -- | Nov 11, 2025 |
 Yoon Hankil | Director | Grant/Award | 10.0K | -- | Nov 11, 2025 |
 O'DONNELL CAROL A | Director | Grant/Award | 10.0K | -- | Nov 11, 2025 |
| Yoon Hankil | Director | Grant/Award | 3.0K | -- | Oct 15, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
Apimeds Inc. · joint filing· may incl. warrants· filed May 2026 | 431.7K | 28.0% | 13D |
Ayrton Capital LLC · filed Feb 2026 | 0+139.7K via conversion | 9.1% | 13G |
 Emerson Erik C. Chief Executive Officer, Director | 75.0K | 4.9% | FORM 4 |
 Koo Jakap Director | 64.4K | 4.2% | FORM 4 |
 Kim Christopher Chairman and CMO, Director | 27.8K | 1.8% | FORM 4 |
Hemenway Trust Co LLC | 27.4K | 1.8% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 6.4K | 0.4% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 3.5K | 0.2% | 13F |
VANGUARD FIDUCIARY TRUST CO | 2.4K | 0.2% | 13F |
JANE STREET GROUP, LLC | 1.6K | 0.1% | 13F |
Insiders
- Koo JakapDirector
- Kogan ElonaDirector
- Weintraub BennettDirector
- Yoon HankilDirector
- O'DONNELL CAROL ADirector
- Kim ChristopherChairman and CMO
- Emerson Erik C.Chief Executive Officer
- Inscobee Inc.10% Owner
based on 1.54M shares outstanding
US30d Avg
4.97M
60d Avg
5.78M
90d Avg
3.82M